These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1442 related items for PubMed ID: 27783993

  • 1. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX, Qi Y, Zhang J, Liu Y, Xu WH, Xu J, Hu HG, Wu QY, Wang Y, Zhang JP.
    Oncotarget; 2016 Nov 29; 7(48):79544-79556. PubMed ID: 27783993
    [Abstract] [Full Text] [Related]

  • 2. Matrine derivative WM130 inhibits hepatocellular carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways.
    Qian L, Liu Y, Xu Y, Ji W, Wu Q, Liu Y, Gao Q, Su C.
    Cancer Lett; 2015 Nov 01; 368(1):126-134. PubMed ID: 26259512
    [Abstract] [Full Text] [Related]

  • 3. A novel matrine derivate inhibits differentiated human hepatoma cells and hepatic cancer stem-like cells by suppressing PI3K/AKT signaling pathways.
    Liu Y, Qi Y, Bai ZH, Ni CX, Ren QH, Xu WH, Xu J, Hu HG, Qiu L, Li JZ, He ZG, Zhang JP.
    Acta Pharmacol Sin; 2017 Jan 01; 38(1):120-132. PubMed ID: 27773936
    [Abstract] [Full Text] [Related]

  • 4. Differentiation therapy of hepatocellular carcinoma by inhibiting the activity of AKT/GSK-3β/β-catenin axis and TGF-β induced EMT with sophocarpine.
    Zhang PP, Wang PQ, Qiao CP, Zhang Q, Zhang JP, Chen F, Zhang X, Xie WF, Yuan ZL, Li ZS, Chen YX.
    Cancer Lett; 2016 Jun 28; 376(1):95-103. PubMed ID: 26945965
    [Abstract] [Full Text] [Related]

  • 5. [Matrine suppresses stemness of hepatocellular carcinoma cells by regulating β-catenin signaling pathway].
    Dai M, Cai Z, Chen N, Li J, Wen J, Tan L, Guo D.
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Oct 30; 39(10):1239-1245. PubMed ID: 31801708
    [Abstract] [Full Text] [Related]

  • 6. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M, Chen C, Geng J, Han D, Wang T, Xie T, Wang L, Wang Y, Wang C, Lei Z, Chu X.
    Cancer Lett; 2017 Jul 10; 398():12-21. PubMed ID: 28377178
    [Abstract] [Full Text] [Related]

  • 7. 6-C-(E-Phenylethenyl)Naringenin Attenuates the Stemness of Hepatocellular Carcinoma Cells by Suppressing Wnt/β-Catenin Signaling.
    Kang Q, Gong J, Wang M, Wang Q, Chen F, Cheng KW.
    J Agric Food Chem; 2019 Dec 18; 67(50):13939-13947. PubMed ID: 31769973
    [Abstract] [Full Text] [Related]

  • 8. Downregulation of Cancer Stemness by Novel Diterpenoid Ovatodiolide Inhibits Hepatic Cancer Stem Cell-Like Traits by Repressing Wnt/[Formula: see text]-Catenin Signaling.
    Liu M, Bamodu OA, Kuo KT, Lee WH, Lin YK, Wu ATH, M H, Tzeng YM, Yeh CT, Tsai JT.
    Am J Chin Med; 2018 Dec 18; 46(4):891-910. PubMed ID: 29792038
    [Abstract] [Full Text] [Related]

  • 9. PAF enhances cancer stem cell properties via β-catenin signaling in hepatocellular carcinoma.
    Li M, Mu XD, Song JR, Zhai PT, Cheng Y, Le Y, Li ZB.
    Cell Cycle; 2021 May 18; 20(10):1010-1020. PubMed ID: 33970778
    [Abstract] [Full Text] [Related]

  • 10. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway.
    Mao J, Wang D, Wang Z, Tian W, Li X, Duan J, Wang Y, Yang H, You L, Cheng Y, Bian J, Chen Z, Yang Y.
    Cancer Lett; 2016 Sep 28; 380(1):134-43. PubMed ID: 27349166
    [Abstract] [Full Text] [Related]

  • 11. NOR1 Suppresses Cancer Stem-Like Cells Properties of Tumor Cells via the Inhibition of the AKT-GSK-3β-Wnt/β-catenin-ALDH1A1 Signal Circuit.
    Wang W, Yi M, Chen S, Li J, Zhang H, Xiong W, Li G, Li X, Xiang B.
    J Cell Physiol; 2017 Oct 28; 232(10):2829-2840. PubMed ID: 27891591
    [Abstract] [Full Text] [Related]

  • 12. Zinc finger protein X-linked promotes expansion of EpCAM+ cancer stem-like cells in hepatocellular carcinoma.
    Wang C, Fu SY, Wang MD, Yu WB, Cui QS, Wang HR, Huang H, Dong W, Zhang WW, Li PP, Lin C, Pan ZY, Yang Y, Wu MC, Zhou WP.
    Mol Oncol; 2017 May 28; 11(5):455-469. PubMed ID: 28156061
    [Abstract] [Full Text] [Related]

  • 13. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L, Wang X, Jia T, Wei W, Chua MS, So S.
    Oncotarget; 2015 Sep 22; 6(28):25390-401. PubMed ID: 26246473
    [Abstract] [Full Text] [Related]

  • 14. A Novel Small-molecule WNT Inhibitor, IC-2, Has the Potential to Suppress Liver Cancer Stem Cells.
    Seto K, Sakabe T, Itaba N, Azumi J, Oka H, Morimoto M, Umekita Y, Shiota G.
    Anticancer Res; 2017 Jul 22; 37(7):3569-3579. PubMed ID: 28668848
    [Abstract] [Full Text] [Related]

  • 15. Lidamycin inhibits tumor initiating cells of hepatocellular carcinoma Huh7 through GSK3β/β-catenin pathway.
    Chen Y, Yu D, Zhang C, Shang B, He H, Chen J, Zhang H, Zhao W, Wang Z, Xu X, Zhen Y, Shao RG.
    Mol Carcinog; 2015 Jan 22; 54(1):1-8. PubMed ID: 23857500
    [Abstract] [Full Text] [Related]

  • 16. IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft.
    Martins-Neves SR, Paiva-Oliveira DI, Fontes-Ribeiro C, Bovée JVMG, Cleton-Jansen AM, Gomes CMF.
    Cancer Lett; 2018 Feb 01; 414():1-15. PubMed ID: 29126913
    [Abstract] [Full Text] [Related]

  • 17. Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways.
    Cheng Z, Yuan X, Qu Y, Li X, Wu G, Li C, Zu X, Yang N, Ke X, Zhou J, Xie N, Xu X, Liu S, Shen Y, Li H, Zhang W.
    Cancer Lett; 2017 Sep 10; 403():195-205. PubMed ID: 28645563
    [Abstract] [Full Text] [Related]

  • 18. 8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of β-catenin.
    Quan MF, Xiao LH, Liu ZH, Guo H, Ren KQ, Liu F, Cao JG, Deng XY.
    World J Gastroenterol; 2013 Sep 10; 19(43):7680-95. PubMed ID: 24431896
    [Abstract] [Full Text] [Related]

  • 19. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
    Leung HW, Leung CON, Lau EY, Chung KPS, Mok EH, Lei MML, Leung RWH, Tong M, Keng VW, Ma C, Zhao Q, Ng IOL, Ma S, Lee TK.
    Cancer Res; 2021 Jun 15; 81(12):3229-3240. PubMed ID: 33903122
    [Abstract] [Full Text] [Related]

  • 20. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.